Tubulis GmbH

Exciting News! Tubulis is one of Fierce Biotech’s 2024 #Fierce15 #biotech companies! Being selected for this prestigious industry award is an important recognition of our leadership position in the #ADC space and for the potential of our unique approach aiming to push the boundaries of ADCs. It is also a testament to all the hard work our team is putting in to drive innovation and realize our mission of improving the outcomes for cancer patients. We therefore want to thank every team member and our Board for their contributions! With our upsized Series B2 #financing in March, the start of our first clinical trial in June and the granting of #FDA Fast Track status for our lead candidate briefly afterwards, 2024 is a pivotal year for us. We are highly motivated to further building on this momentum and would like to thank the Fierce Biotech team for selecting us as one of this year’s fiercest companies! Click here to read the full announcement: https://bit.ly/4dmg2gY

Exciting News! Tubulis is one of Fierce Biotech’s 2024 #Fierce15 #biotech companies! Being selected for this prestigious industry award is an important recognition of our leadership position in the #ADC space and for the potential of our unique approach aiming to push the boundaries of ADCs. It is also a testament to all the hard work our team is putting in to drive innovation and realize our mission of improving the outcomes for cancer patients. We therefore want to thank every team member and our Board for their contributions! With our upsized Series B2 #financing in March, the start of our first clinical trial in June and the granting of #FDA Fast Track status for our lead candidate briefly afterwards, 2024 is a pivotal year for us. We are highly motivated to further building on this momentum and would like to thank the Fierce Biotech team for selecting us as one of this year’s fiercest companies! Click here to read the full announcement: https://bit.ly/4dmg2gY

Big fun at the B2Run event in Munich! The Tubulis team participated with over 30,000 other runners crossing the finish line in the Olympic stadium.

The latest Flot.bio episode is out now! Listen in to hear Dominik Schumacher, our CEO, and Philip Hemme discuss Tubulis’ journey and the advancements we're making in the ADC biotech space. A big thank you to the Flot.bio team for featuring Dominik and Tubulis!

Our CEO Dominik Schumacher recently had the pleasure to welcome Philip Hemme to our office in Munich, where they recorded a new Flot.bio #podcast episode. They discussed opportunities and challenges #biotech founders are facing, how to successfully scale a company and securing the necessary funding on the way, and of course also the future of #ADCs, our favorite drug class. Thank you for the great exchange, Philip! Stay tuned for the full-length podcast episode, which will be available soon!

Shortly after announcing the dosing of our first patient, we received Fast Track designation by the FDA for TUB-040 in platinum-resistant ovarian cancer (OC). OC is the leading cause of death among women diagnosed with gynecological cancers, and nearly all patients who don't respond to platinum therapies will sooner or later develop resistance. Once resistant, outcomes are poor with a median survival of less than 16 months, leaving patients in desperate need of new treatment options. The Fast Track status granted by the FDA brings us one step closer to our goal of bringing the true value of ADCs to patients and will allow us to accelerate the development of TUB-040.   Read the full press release here: https://bit.ly/3RLXGNE For more information on our clinical trial or technology visit https://lnkd.in/dMpvdaSw or www.tubulis.com

Thank you Clarivate for Life Sciences & Healthcare for selecting us as an #ADC company to watch and featuring us in your comprehensive overview of the ADC space. The report highlights the different approaches to developing ADCs, their unique characteristics and the technological advances that fuel innovation. At Tubulis GmbH, we create uniquely matched ADCs with superior biophysical properties. By combining novel proprietary technologies and disease-specific biological insights our goal is to deliver better outcomes for solid tumor patients.   Looking to learn more about Tubulis? Read the report below or visit https://tubulis.com/

With the IND approval from the FDA, we dosed our first patient in the US today in our Phase I/IIa study, NAPISTAR 1-01. Entering the clinic with our first candidate from our growing pipeline of next-generation #ADCs marks an important milestone for Tubulis and we look forward to bringing the true value of ADCs to patients with solid tumors.   The first-in-human trial is designed to evaluate the safety, tolerability, pharmacokinetics, and efficacy of TUB-040, one of our lead candidates, as a monotherapy in patients with platinum-resistant, high-grade #OvarianCancer (PROC) or relapsed/refractory adenocarcinoma non-small cell lung cancer (#NSCLC), who have exhausted all other available treatment options. TUB-040 is a topoisomerase-I-based ADC targeting NaPi2b, which showed superior biophysical properties in preclinical studies indicating a high potential to improve efficient long-term anti-tumor responses.   Find the full press release here: https://bit.ly/3Xydc3K. If you want to read more on our proprietary suite of platform technologies and vision to usher in a new ADC era for better patient outcomes at www.tubulis.com

We are honored to be the recipient of "The Emerging Star Award" at the European Mediscience Awards 2024. We sincerely thank the organizers and the jury for recognizing the potential of Tubulis, an achievement that reflects our ongoing commitment to overcoming the key limitations of current #ADC technologies.   We also want to thank our whole team for their hard work and dedication. Together, we have translated our deep scientific expertise into a broad suite of proprietary technologies that enable the combination of novel #tumor targets and previously inaccessible payloads in a safe and efficient way, aiming to bring the true potential of ADCs to #patients in need.   Learn more about our mission and uniquely matched pipeline candidates at www.tubulis.com.   #Emergingstar #EMA24

Our CEO, Dominik Schumacher, and Ingo Lehrke, our CBO, are looking forward to participating in the upcoming J.P. Morgan European #Healthcare Forum on June 20th in London, where they will connect with key players in the #biotech and financial community. If you also happen to be in London, take the opportunity to discuss how we aim to realize the full therapeutic potential of #ADCs, our latest positive #pipeline data and upcoming developments at Tubulis, including the start of our first #ClinicalTrial in #SolidTumors just ahead. Send a direct message to Ingo here on LinkedIn to schedule a meeting on-site.   For further information around our unique suite of #ADC technologies and pipeline candidates, visit www.tubulis.com